Summit Therapeutics plc Summit To Present On Pipeline And Strategy For Its New Classes Of Antibiotics At Asm Microbe 2019

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Summit to Present on Pipeline and Strategy for its New Classes of 
Antibiotics at ASM Microbe 2019 
 
   Oxford, UK, and Cambridge, MA, US, 20 June 2019 -- Summit Therapeutics 
plc (NASDAQ: SMMT, AIM: SUMM) today announced that it will present on 
its pipeline and strategy for the Company's new classes of antibiotics 
at the American Society for Microbiology Microbe conference taking place 
20-24 June 2019 in San Francisco, CA. 
 
   "Developing new classes of antibiotics is critical to the fight against 
antimicrobial resistance. One of our new class antibiotics, SMT-571, has 
the potential to treat gonorrhoea, an urgent healthcare threat with 
increasing numbers of cases alongside the spread of drug resistant 
infections. In preclinical data being presented at ASM Microbe, SMT-571 
demonstrated the ability to readily kill bacteria which have become 
extensively resistant to antibiotics already on the market," said Dr 
David Roblin, President of R&D of Summit. "With truly novel antibiotics, 
we believe we are well placed to execute development strategies that 
have the potential to demonstrate significant advantages over current 
standards of care, both in terms of improving patient outcomes and in 
reducing healthcare costs." 
 
   Details of the presentations are as follows: 
 
   Date: 21 June 2019 
 
   Time: 2:52-3:03pm PDT 
 
   Session: Pharma Pipeline Update: Part I 
 
   Location: AAR Track Hub (Booth 5053) -- Learn -- Exhibit and Poster Hall 
3 
 
   Summary: Summit has a unique three-pronged strategy in infectious 
diseases aimed at creating a successful, fully-integrated company. The 
Company focuses on new science to discover new classes of antibiotics 
targeted to treat specific infections. Summit's pipeline currently 
contains late-stage clinical and preclinical programmes for infections 
caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae, and the 
Company's Discuva Platform enables the expansion of this pipeline. 
Summit designs creative development programmes aimed to show significant 
advantages over current standards of care. Finally, Summit looks to 
achieve commercial success by demonstrating both clinical and economic 
advantages of its antibiotics over currently available treatments. 
 
   Date: 23 June 2019 
 
   Time: 10:30am-4:00pm PDT 
 
   Session: New Antimicrobial Agents (pre-phase 2): Inhibitors for Novel 
Targets (1) 
 
   Location: Exhibit and Poster Hall P589 
 
   Title: 
https://www.globenewswire.com/Tracker?data=bQhFykQxlAbHrPJp7e2toqNmRn4Jd0RK20yiRx3xPDSRmsgg-9mpj1HVcx8pg24VA7ESPvfiycjm6i2P-V8P1cEar7HidBMzdE412srMfOk07yemKOiy0XQlZ395bDjW-noBlXlIU2KdQXWEKnL8yLVYuQH2-Lc3o5hl56zqMc6Kxu0wxVZUPJ_Hq0aAWcTh4DbZBzMg74s90fu2R0APXlYjr9nzNrFaAI8-fCoupX2HRzUttobL-Fa97II3BD2jNhUgLzeC3KCKGtULcHbFfA9GxXC4pfecKitnZCzXwh4= 
In Vitro Activity of SMT-571 and Comparators against Clinical Isolates 
and Reference Strains of Neisseria gonorrhoeae 
 
   Authors: P. Meo, C. Mason, N. Khan, of Summit Therapeutics and M. Unemo 
and S. Jacobsson of Örebro University 
 
   Summary: Preclinical data showed SMT-571 to be highly potent against 262 
clinical strains of N. gonorrhoeae. This comprehensive panel of 
gonorrhoea strains, obtained from 1991 to 2018, was designed to be 
geographically and genetically diverse and include strains that are 
extensively- and multi-drug resistant, including ones resistant to 
ceftriaxone, the current standard of care for gonorrhoea. SMT-571, which 
works by a new mechanism of action targeting cell-division, was shown to 
be equally potent against all strains tested. It had a minimum 
inhibitory concentration of 0.064 to 0.125 mg/L against the strains, 
including those that are not susceptible to ceftriaxone. Significantly, 
SMT-571 did not show cross-resistance with any antibiotic currently or 
previously used to treat gonorrhoea infections. 
 
   A copy of the presentations will be available at the start of the 
sessions in the Publications section of the Company's website: 
https://www.globenewswire.com/Tracker?data=RQjk8auYt7mmLShaPk9jyWzzOeiM_Jx_5uk-yrfFE-5CsWn9D0Zsvsb7ilpXjdlskN893kvhPPyXyvb5KwlO7Rx-G9kUZak1-SlYxkXRmgg= 
www.summitplc.com. 
 
   About Gonorrhoea 
 
   It is estimated by the World Health Organization ('WHO') that there are 
approximately 78 million new cases of gonorrhoea globally per year. 
Neisseria gonorrhoeae has consistently developed resistance to each 
class of antibiotics recommended for treatment and there is now only one 
treatment recommended by the CDC and European evidence-based guidelines, 
a combination of two antibiotics. There are currently no other 
recommended antibiotics that can be effectively deployed to target the 
disease. The WHO ranks as "High" the priority of R&D investment into the 
search for antibiotics which are effective against N. gonorrhoeae and in 
August 2018, the CDC stated that in light of increased problems with 
resistance, additional treatment options were urgently required. 
 
   About SMT-571 
 
   SMT-571 is a small molecule, novel mechanism antibiotic in preclinical 
development for the treatment of gonorrhoea. SMT-571 is designed to be 
an oral treatment with potential activity across the three sites of 
gonorrhea infection: urogenital, rectal and pharyngeal. Preclinical 
studies have shown SMT-571 to have potent activity across a wide range 
of N. gonorrhoeae strains, including multi- and extensively-drug 
resistant ones. SMT-571 was identified using Summit's Discuva Platform, 
which can identify novel targets, elucidate mechanisms of action and 
optimise against bacterial resistance. 
 
   The development of SMT-571 is supported by the Cooperative Agreement 
Number IDSEP160030 from ASPR/BARDA and by an award from Wellcome Trust, 
as administered by CARB-X. The content of this announcement is solely 
the responsibility of the authors and does not necessarily represent the 
official views of the Department of Health and Human Services Office of 
the Assistant Secretary for Preparedness and Response, other funders, or 
CARB-X. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for 
infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae 
and are using our proprietary Discuva Platform to expand our pipeline. 
For more information, visit www.summitplc.com and follow us on Twitter 
@summitplc. 
 
   Contacts 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)    Tel:                  44 (0)1235 443 951 
Michelle Avery (US office)                                         [phone] 
 
Cairn Financial Advisers LLP (Nominated 
 Adviser)                                 Tel:                 [phone] 
Liam Murray / Tony Rawlinson 
 
N+1 Singer (Joint Broker)                 Tel:                 [phone] 
Aubrey Powell / Jen Boorer, Corporate 
 Finance 
 Tom Salvesen, Corporate Broking 
 
Bryan Garnier & Co Limited (Joint 
 Broker)                                  Tel:                 [phone] 
Phil Walker / Dominic Wilson 
MSL Group (US)                            Tel:                     [phone] 
                                                        mailto:[e-mail] 
Jon Siegal                                                     [e-mail] 
                                                 --------------------------------- 
 
Consilium Strategic Communications (UK)   Tel:                 [phone] 
Mary-Jane Elliott / Sue Stuart /                 mailto:[e-mail] 
                                                  [e-mail] 
                                                 --------------------------------- 
Lindsey Neville 
 
 
   Summit Forward-looking Statements 
 
   Any statements in this press release about the Company's future 
expectations, plans and prospects, including but not limited to, 
statements about the clinical and preclinical development of the 
Company's product candidates, the therapeutic potential of the Company's 
product candidates, the potential commercialisation of the Company's 
product candidates, the sufficiency of the Company's cash resources, the 
timing of initiation, completion and availability of data from clinical 
trials, the potential submission of applications for marketing approvals 
and other statements containing the words "anticipate," "believe," 
"continue," "could," "estimate," "expect," "intend," "may," "plan," 
"potential," "predict," "project," "should," "target," "would," and 
similar expressions, constitute forward-looking statements within the 
meaning of The Private Securities Litigation Reform Act of 1995. Actual 
results may differ materially from those indicated by such 
forward-looking statements as a result of various important factors, 
including: the uncertainties inherent in the initiation of future 
clinical trials, availability and timing of data from ongoing and future 
clinical trials and the results of such trials, whether preliminary 
results from a clinical trial will be predictive of the final results of 
that trial or whether results of early clinical trials or preclinical 
studies will be indicative of the results of later clinical trials, 
expectations for regulatory approvals, laws and regulations affecting 
government contracts and funding awards, availability of funding 
sufficient for the Company's foreseeable and unforeseeable operating 
expenses and capital expenditure requirements and other factors 
discussed in the "Risk Factors" section of filings that the Company 
makes with the Securities and Exchange Commission, including the 
Company's Annual Report on Form 20-F for the fiscal year ended 31 
January 2019. Accordingly, readers should not place undue reliance on 
forward-looking statements or information. In addition, any 

forward-looking statements included in this press release represent the 
Company's views only as of the date of this release and should not be 
relied upon as representing the Company's views as of any subsequent 
date. The Company specifically disclaims any obligation to update any 
forward-looking statements included in this press release. 
 
   -END- 
 
 
 
 

(END) Dow Jones Newswires

June 20, 2019 07:00 ET (11:00 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.